Cartia XT (Actavis) – Foreign Substance Presence (2015)
Class III: A situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences
Class III recall indicates unlikely adverse health consequences.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Cartia XT (diltiazem HCl extended-release capsules, USP), Once-A-Day Dosage, 300 mg, 90-count bottles, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA --- NDC 62037-0600-90
Brand
Actavis Laboratories, FL, Inc.
Lot Codes / Batch Numbers
Lot # 956000M, Exp. Aug 2016, UPC 3-6203760090-6
Products Sold
Lot # 956000M, Exp. Aug 2016; UPC 3-6203760090-6
Actavis Laboratories, FL, Inc. is recalling Cartia XT (diltiazem HCl extended-release capsules, USP), Once-A-Day Dosage, 300 mg, 90-count bottle due to Presence of Foreign Substance; fine residue or dust identified as aluminum may be on exterior of the capsule shell. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Presence of Foreign Substance; fine residue or dust identified as aluminum may be on exterior of the capsule shell
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026